C2Maps: a network pharmacology database with comprehensive disease-gene-drug connectivity relationships

BMC Genomics

Table 4 Performance assessment of C²Maps in varying cancers.

	Bladder	Breast	Leukemia	Lung	Lymphoma	Melanoma	Ovary	Pancreas	Prostate
Sensitivity	80.84%	79.80%	83.16%	78.44%	81.20%	77.39%	80.88%	84.99%	82.84%
Specificity	87.11%	84.91%	86.11%	89.37%	87.60%	91.53%	84.34%	86.45%	88.38%
ACC	86.70%	84.27%	85.63%	87.86%	86.78%	90.17%	84.09%	86.34%	87.93%
PPV	30.51%	43.01%	53.39%	54.06%	48.92%	49.24%	28.84%	33.82%	38.88%
F-Score	44.30%	55.89%	65.03%	64.01%	61.05%	60.19%	42.52%	48.38%	52.92%

The experiment were performed using a protein interaction confidence minimum threshold of 3 star and above (i.e., reliability score of >0.75) and retrieved drug p-value at a minimum threshold of 0.05. The detailed evaluation procedures and measurement definitions, they can be found in the "Method FAQ" page of our C²Maps website and as supplemental materials.

ISSN: 1471-2164